



賴志河 Chih-Ho Lai

教授 Professor

研究室：感染免疫研究室

電話：03-2118800 ext 5116

傳真：03-2118700

信箱：chlai@mail.cgu.edu.tw

個人網頁網址：<https://sites.google.com/a/gap.cgu.edu.tw/infection-and-immunity/>

學經歷

Education

- 2000 – 2005 Ph.D., Department of Life Science, National Tsing Hua University
1994 – 1996 M.S., Graduate Institute of Microbiology and Immunology, National Defense Medical Center
1990 – 1994 B.S., Department of Medical Technology, China Medical College

Research experiences

- 2015 Professor, Department of Microbiology and Immunology, Chang Gung University
2013 Professor, Department of Microbiology, School of Medicine, China Medical University
2011 Assistant Professor, Department of Urology, The University of Texas Southwestern Medical Center
2009 Associate Professor, Department of Microbiology, School of Medicine, China Medical University
2005 Post-doctoral fellow, Infectious Disease Control and International Medicine, Niigata University, Japan

研究方向

我們實驗室主要的研究方向是探討微生物致病機轉與宿主免疫反應，並開發有效之治療藥物。研究之微生物主題包含：幽門螺旋桿菌(*Helicobacter pylori*)、空腸彎曲桿菌(*Campylobacter jejuni*)、鏈球菌(*Streptococcus pyogenes*)、嗜血桿菌(*Haemophilus influenzae*)等人類常見致病菌與免疫細胞之相互作用。此外，我們也有探討細菌毒素應用於治療癌症幹細胞(cancer stem cells)、癌症生物學及轉譯醫學等臨床議題，希望能將研究成果應用於癌症之治療。我們非常歡迎對感染免疫學及癌症生物學領域有興趣的大學部專題生、碩、博班研究生一起參與實驗室的研究。

著作(最近五年) (*, corresponding author)

- **Lai CH***, Huang JC, Cheng HH, Wu MC, Huang MZ, Hsu HY, Chen YA, Hsu CY, Pan YJ, Chu YT, Chen TJ, Wu YF, Sit WY, Liu JS, Chiu YF, Wang HJ, Wang WC*. *Helicobacter pylori* cholesterol glucosylation modulates autophagy for increasing intracellular survival in macrophages. *Cell Microbiol.* 2018;27:e12947 doi: 10.1111/cmi.12947. [Epub ahead of print].
- Chen YA, Shih HW, Lin YC, Hsu HY, Wu TF, Tsai CH, Wu CL, Wu HY, Hsieh JT, Tang CH, **Lai CH***. Simvastatin sensitizes radioresistant prostate cancer cells by compromising DNA double-strand break repair. *Front Pharmacol.* 2018;13:600.
- Tsai FJ, Li TM, Cheng CF, Wu YC, **Lai CH**, Ho TJ, Liu X, Tsang H, Lin TH, Liao CC, Huang SM, Li JP, Lin JC, Lin CC, Liang WM, Lin YJ. Effects of Chinese herbal medicine on hyperlipidemia and the risk of cardiovascular disease in HIV-infected patients in Taiwan. *J Ethnopharmacol.* 2018;12:71-80.
- Chen YA, Lin YJ, Lin CL, Lin HJ, Wu HS, Hsu HY, Sun YC, Wu HY, **Lai CH***, Kao CH*. Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia. *Front Pharmacol.* 2018;22:225.
- Chen YA, Lien HM, Kao MC, Lo UG, Lin LC, Lin CJ, Chang SJ, Chen CC, Hsieh JT, Lin H, Tang CH, **Lai CH***. Sensitization of radioresistant prostate cancer cells by resveratrol isolated from *Arachis hypogaea* stems. *PLoS One.* 2017;12(1):1-16.

- Lin LC, Gao AC, **Lai CH***, Hsieh JT*, Lin H*. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes. *Cancer Lett.* 2017;391:74-82.
- Lin HJ, Liu HH, Lin CD, Kao MC, Chen YA, Chiang-Ni C, Jiang ZP, Huang MZ, Lin CJ, Lo UG, Lin LC, Lai CK, Lin H, Hsieh JT, Chiu CH, **Lai CH***. Cytolethal distending toxin enhances radiosensitivity in prostate cancer cells by regulating autophagy. *Front Cell Infect Microbiol.* 2017; 7(223):1-8.
- Peng YH, Chen CK, Su CH, Liao WC, Muo CH, Hsia TC, Sung FC, **Lai CH***, Kao CH*. Increased risk of chronic obstructive pulmonary disease among patients with *Helicobacter pylori* infection: a population-based cohort study. *Clin Respir J.* 2017;11:558-565.
- Liao WC, Huang MZ, Wang ML, Lin CJ, Lu TL, Lo HR, Pan YJ, Sun YC, Kao MC, Lin HJ, **Lai CH***. Statin decreases *Helicobacter pylori* burden in macrophages by promoting autophagy. *Front Cell Infect Microbiol.* 2017;6(203):1-11.
- Lin CJ, Liao WC, Chen YA, Lin HJ, Feng CL, Lin CL, Lin YJ, Kao MC, Huang MZ, **Lai CH***, Kao CH*. Statin therapy is associated with reduced risk of peptic ulcer disease in the Taiwanese population. *Front Pharmacol.* 2017; 8(210):1-8.
- Lin HJ, Hsu FY, Chen WW, Lee CH, Lin YJ, Chen YY, Chen CJ, Huang MZ, Kao MC, Lai HC, **Lai CH***. *Helicobacter pylori* activates HMGB1 expression and recruits RAGE into lipid rafts to promote inflammation in gastric epithelial cells. *Front Immunol.* 2016;7:1-11.
- Lin CJ, Lien HM, Lin HJ, Huang CL, Kao MC, Chen YA, Wang CK, Chang HY, Chang YK, **Lai CH***. Modulation of T cell response by *Phellinus linteus*. *J Biosci Bioeng.* 2016;121:84-88.
- Lin CJ, Liao WC, Lin HJ, Hsu YM, Lin CL, Chen YA, Feng CL, Chen CJ, Kao MC, **Lai CH***, Kao CH*. Statins attenuate *Helicobacter pylori* CagA translocation and reduce incidence of gastric cancer. *PLoS One.* 2016;11(1):1-16.
- Huang PH, Chen MC, Peng YT, Kao WH, Chang CH, Wang YC, **Lai CH**, Hsieh JT, Wang JH, Lee YT, Lin E, Yue CH, Wang HY, You SC, Lin H. Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth. *Cancer Res.* 2016;76(23):6888-6900.
- Lai CH***, Huang CJ, Chiang-Ni C, Li JP, Wu LT, Wu HS, Sun YC, Lin ML, Lee JF, Lin HJ. Mixed infections of *Helicobacter pylori* isolated from patients with gastrointestinal diseases in Taiwan. *Gastroenterol Res Pract.* 2016;2016:1-5.
- Lai CK, Chen YA, Lin CJ, Lin HJ, Kao MC, Huang MZ, Lin YH, Chiang-Ni C, Chen CJ, Lo UG, Lin LC, Lin H, Hsieh JT, **Lai CH***. Molecular mechanisms and potential clinical applications of *Campylobacter jejuni* cytolethal distending toxin. *Front Cell Infect Microbiol.* 2016;6:1-8.
- Huang WY, Lin JN, Hsieh JT, Chou SC, **Lai CH**, Yun EJ, Lo UG, Pong RC, Lin JH, Lin YH. Nanoparticle targeting CD44-positive cancer cells for site-specific drug delivery in prostate cancer therapy. *ACS Appl Mater Interfaces.* 2016;8(45):30722-30734.
- Tsou YA, Lin CD, Chen HC, Hsu HY, Wu LT, Chiang-Ni C, Chen CJ, Wu TF, Kao MC, Chen YA, Peng MT, Tsai MH, Chen CM, **Lai CH***. Interleukin-13 inhibits lipopolysaccharide-induced BPIFA1 expression in nasal epithelial cells. *PLoS One.* 2015;10(12):1-16.
- Tsou YA, Lin CD, Hsu HY, Peng MT, Kuo YY, Tien N, Li JP, Wang CK, Wu HS, Tsai MH, Chen CM, **Lai CH***. Association of β -lactam-sensitive *Haemophilus influenzae* type b with adenoid biofilm formation in patients with adenoidectomy surgery. *Surg Infect.* 2015;16:709-715.
- Lai CK, Su JC, Lin YH, Chang CS, Feng CL, Lin HJ, Tseng GC, Hsieh JT, Su HL, **Lai CH***. Involvement of cholesterol in *Campylobacter jejuni* cytolethal distending toxin-induced pathogenesis. *Future Microbiol.* 2015;10:489-501.
- Hung CL, Cheng HH, Hsieh WC, Tsai ZT, Tsai HK, Chu CH, Hsieh WP, Chen YF, Tsou Y, **Lai CH***, Wang WC*. The CrdRS two-component system in *Helicobacter pylori* responds to nitrosative stress. *Mol Microbiol.* 2015;97:1128-41.
- Lin YH, Chen ZR, **Lai CH**, Hsieh CH, Feng CL. Active targeted nanoparticles for oral administration of gastric cancer therapy. *Biomacromolecules.* 2015;16:3021-32.
- Gandee L, Hsieh JT, Sperandio V, Moreira CG, **Lai CH**, Zimmern PE. The efficacy of immediate versus delayed antibiotic administration on bacterial growth and biofilm production of selected strains of uropathogenic *Escherichia coli* and *Pseudomonas aeruginosa*. *Int Braz J Urol.* 2015;41(1):67-77.
- Chen CM, Liu JJ, Chou CW, **Lai CH***, Wu LT*. RpA, an extracellular protease similar to the metalloprotease of serralyisin family, is required for pathogenicity of *Ralstonia pickettii*. *J App Microbiol.* 2015;119:1101-1111.
- Kao MC, Yerra KR, Hsieh YW, Weng SH, Lu TL, Tzeng David-TW, Liu JJ, Lin CJ, **Lai CH***, Tzeng YW*. A cyclohexadepsipeptide from entomogenous fungi *Metarhizium anisopliae* inhibits the *Helicobacter pylori* induced pathogenesis through attenuation of vacuolating cytotoxin-A activity. *Process Biochem.* 2015;50:134-139.

- Lin CD, Kou YY, Liao CY, Li CH, Huang SP, Cheng YM, Liao WC, Wu PL, Kang JJ, Lee CC, **Lai CH***. Zinc oxide nanoparticles impair bacterial clearance by macrophages. *Nanomedicine*. 2014;9:1327–1339.
- **Lai CH***, Chang CS, Liu HH, Tsai YS, Yu YL, Lai CK, Gandee L, Pong RC, Hsu HW, Yu L, Saha D, and Hsieh JT. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. *Oncotarget*. 2014;5:5523-5534.
- Lin CJ, Lien HM, Chang HY, Huang CL, Liu JJ, Chang YC, Chen CC, **Lai CH***. Biological evaluation of *Phellinus linteus*-fermented broths as anti-inflammatory agents. *J Biosci Bioeng*. 2014;118:88-93.
- Lai CK, Lu YL, Hsieh JT, Tsai SC, Feng CL, Tsai YS, Tsai PC, Su HL, Lin YH, **Lai CH***. Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. *Nanomedicine*. 2014;9:803-817.
- Tsai YS, Lai CL, **Lai CH**, Chang KH, Wu K, Tseng SF, Fazli L, Gleave M, Xiao G, Gandee L, Sharifi N, Moro L, Tzai TS, Hsieh JT*. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. *Oncotarget*. 2014;5:6425-36.
- Lai CK, Yerra KR, Chang KR, Lin CW, Su HL, Chang CS, **Lai CH***, Tzeng YM*. 3,3',4',5'-tetramethoxychalcone inhibits human oral cancer cell proliferation and migration via p53-mediated mitochondrial-dependent apoptosis. *Anticancer Res*. 2014;34:1811-1819.
- **Lai CH***, Lai CK, Lin YJ, Hung CL, Chu CH, Feng CL, Chang CH, Su HL. Characterization of putative cholesterol recognition/interaction amino acid consensus-like motif of *Campylobacter jejuni* cytolethal distending toxin C. *PLoS One*. 2013;8(6):e66202.
- Lin YH, Tsai SC, **Lai CH**, Lee CH, He ZS, Tseng GC. Genipin-cross-linked fucosechitosan/heparin nanoparticles for the eradication of *Helicobacter pylori*. *Biomaterials*. 2013;34:4466-4479.
- Ho CM, Ho MW, Chi CY, Lin CD, Lin CW, Chang HL, Chang YF, Lu JJ, **Lai CH***. Repeated colonization of multidrug-resistant *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex and changes in antimicrobial susceptibilities in surgical intensive care units. *Surg Infect*. 2013;14:43-48.
- **Lai CH**, Perng CL, Lan KH, Lin HJ*. Association of IS605 and cag-PAI of *Helicobacter pylori* isolated from patients with gastrointestinal diseases in Taiwan. *Gastroenterol Res Pract*. 2013;356217:1-5.
- Lien HM, Wang CY, Chang HY, Huang CL, Peng MT, Sing YT, Chen CC, **Lai CH***. Bioevaluation of *Anisomeles indica* extracts and their inhibitory effects on *Helicobacter pylori*-mediated inflammation. *J Ethnopharmacol*. 2013;145:397-401.
- Lu DY, Chen HC, Yang MS, Hsu YM, Lin HJ, Tang CH, Lee CH, Lai CK, Lin CJ, **Lai CH***. Ceramide and TLR4 are mobilized into membrane rafts in response to *Helicobacter pylori* infection in gastric epithelial cells. *Infect Immun*. 2012;80:1823-33.
- Wang HJ, Cheng WC, Cheng HH, **Lai CH**, Wang WC*. *H. pylori* cholesteryl glucosides interfere host membrane phase and affect type IV secretion system function during infection in AGS cells. *Mol Microbiol*. 2012;83:67-84.
- Chang CS, Liu JF, Lin HJ, Lin CD, Tang CH, Lu DY, Chen LY, Kuo SC, **Lai CH***. Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit *Helicobacter pylori*-induced pathogenesis in human gastric epithelial cells. *Eur J Med Chem*. 2012;48:244-54.
- Chiu YF, Sugden B, Chang PJ, Chen LW, Lin YJ, Lan YC, **Lai CH**, Liou JY, Liu ST, Hung CH*. Characterization and intracellular trafficking of Epstein-Barr virus BBLF1, a protein involved in virion maturation. *J Virol*. 2012;86:9647-55.
- Koteswara Y, Lien HM, Lin YH, Hsu YM, **Lai CH***, Tzeng YM*. Antibacterial activities of *Anisomeles indica* constituents and their inhibition effect on *Helicobacter pylori*-induced inflammation in human gastric epithelial cells. *Food Chem*. 2012;132:780-787.
- Lu DY, Tang CH, Chang CH, Maa MC, Fang SH, Hsu YM, Lee CH, **Lai CH***. *Helicobacter pylori* attenuates lipopolysaccharide-induced nitric oxide production by murine macrophages. *Innate Immun*. 2012;18:406-417.